Perspective Therapeutics, Inc. (ticker: CATX) is an NYSE-listed pharma company. DredgeCap's structured extraction of CATX's SEC filings surfaces 2 active risk signals, including 1 auditor-change signal, and 1 late-filing signal. CATX reported $6.34M in revenue and -$26.19M for the period ending 2023-09-30, with operating cash flow of -$31.47M. Cash and equivalents stood at $53.97M (up 21.5% year-over-year). Total assets of $410.77M exceed total liabilities of $63.33M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CATX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Perspective Therapeutics, Inc. (CATX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.